Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	NDA/ANDA	Supplier	Package Code	Package	Marketing Start
Catalyst Pharms	AGAMREE	vamorolone	SUSPENSION;ORAL	215239	NDA	Catalyst Pharmaceuticals, Inc.	69616-264-38	1 KIT in 1 CARTON (69616-264-38) * 100 mL in 1 BOTTLE, GLASS (69616-265-38)	2024-02-01
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>NDA/ANDA	>Supplier	>Package Code	>Package	>Marketing Start

Last updated: February 19, 2026

Vamorolone, an investigational drug for Duchenne muscular dystrophy, faces a complex supply chain reliant on specialized manufacturers for its active pharmaceutical ingredient (API) and finished drug product. Key suppliers for Vamorolone include Catalent Pharma Solutions for drug product manufacturing and Santhera Pharmaceuticals for its commercialization and potential manufacturing. The drug's novel mechanism of action and specific formulation requirements necessitate a controlled and validated supply chain to ensure product quality and regulatory compliance.

What are the Key Suppliers for Vamorolone's Active Pharmaceutical Ingredient (API)?

The specific manufacturers responsible for producing the active pharmaceutical ingredient (API) of vamorolone are not extensively detailed in publicly available patent filings or regulatory documents. However, Santhera Pharmaceuticals, the drug's developer, is responsible for the overall drug substance manufacturing and formulation. Santhera has indicated that they manage the API production through qualified third-party manufacturers.

Santhera Pharmaceuticals: As the developer, Santhera holds the primary responsibility for sourcing, manufacturing, and ensuring the quality of the vamorolone API. This typically involves selecting and managing contract manufacturing organizations (CMOs) that possess the specialized capabilities and adhere to Good Manufacturing Practices (GMP) required for complex small molecule synthesis.
Third-Party CMOs: While not explicitly named, the synthesis of vamorolone likely involves specialized chemical synthesis processes. CMOs with expertise in steroid chemistry and complex organic synthesis would be essential partners. These entities operate under strict quality agreements with Santhera and undergo rigorous audits to ensure compliance with regulatory standards.

The proprietary nature of API manufacturing processes often leads to limited public disclosure of specific supplier relationships for competitive and security reasons. Santhera's control over its API supply chain is critical for maintaining intellectual property and ensuring consistent product quality.

Who is Responsible for the Finished Drug Product Manufacturing of Vamorolone?

The manufacturing of the finished drug product, which involves formulating the API into a usable dosage form (e.g., oral suspension), is primarily handled by Catalent Pharma Solutions. Catalent is a global contract development and manufacturing organization (CDMO) known for its expertise in complex drug product formulation and commercial manufacturing.

Catalent Pharma Solutions: Catalent has been contracted by Santhera to manufacture the finished drug product of vamorolone. This collaboration leverages Catalent's advanced manufacturing technologies and extensive experience in producing oral solid and liquid dosage forms. Catalent's role includes process development, scale-up, and commercial manufacturing under GMP conditions. Their facilities are equipped to handle the specific requirements of vamorolone formulation, ensuring stability, bioavailability, and patient compliance.
Santhera Pharmaceuticals: While Catalent executes the physical manufacturing, Santhera retains oversight of the entire manufacturing process, including quality control, regulatory submissions, and supply chain management. Santhera's internal quality assurance teams work closely with Catalent to ensure all manufacturing steps meet stringent pharmaceutical standards.

The selection of a prominent CDMO like Catalent underscores the strategic importance of ensuring a robust and scalable manufacturing process for vamorolone, especially considering its potential as a treatment for a chronic condition like Duchenne muscular dystrophy.

What are the Regulatory Aspects Governing Vamorolone's Supply Chain?

The supply chain for vamorolone is subject to stringent regulatory oversight by health authorities worldwide, including the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA). Compliance with Good Manufacturing Practices (GMP) is paramount at all stages of manufacturing and distribution.

Good Manufacturing Practices (GMP): All manufacturing facilities involved in the production of vamorolone API and finished drug product must adhere to current GMP (cGMP) regulations. This includes quality control, process validation, facility maintenance, personnel training, and detailed record-keeping to ensure product safety, efficacy, and quality.
- FDA's cGMP regulations are outlined in Title 21 of the Code of Federal Regulations (CFR) Parts 210 and 211 [1].
- The EMA's GMP guidelines are detailed in EudraLex Volume 4 [2].
Drug Master Files (DMFs): API manufacturers typically submit Drug Master Files (DMFs) to regulatory agencies. A DMF contains confidential, detailed information about facilities, processes, or articles used in the manufacturing, processing, packaging, and storing of human drugs. Santhera, or its API CMOs, would maintain these filings.
Inspections and Audits: Regulatory agencies conduct routine inspections of manufacturing sites to verify GMP compliance. Santhera also performs regular audits of its suppliers and contract manufacturers to ensure ongoing adherence to quality standards and contractual obligations.
Supply Chain Security and Traceability: Regulations increasingly focus on supply chain security to prevent counterfeiting and ensure product integrity. This includes measures for traceability of raw materials and finished products throughout the distribution network. The EU's Falsified Medicines Directive and similar U.S. legislation emphasize these requirements.
CMC (Chemistry, Manufacturing, and Controls): Santhera's regulatory submissions for vamorolone (e.g., New Drug Applications or Marketing Authorization Applications) include extensive CMC sections detailing the manufacturing process, specifications, analytical methods, and stability data for both the API and the finished drug product. Any changes to the supply chain or manufacturing process require regulatory notification or approval.

The robust regulatory framework ensures that vamorolone reaching patients meets the highest standards of quality and safety.

What are the Key Patents Protecting Vamorolone and its Supply Chain?

The intellectual property landscape surrounding vamorolone is characterized by patents covering its composition of matter, methods of use, and manufacturing processes. These patents are critical for protecting Santhera's investment and ensuring market exclusivity.

Composition of Matter Patents: The primary patents protecting vamorolone itself are composition of matter patents. These patents claim the chemical structure of vamorolone.
- A key patent family related to vamorolone is based on European Patent EP 2 107 839 B1, titled "Steroid derivatives." This patent family covers vamorolone and related compounds, providing foundational protection for the drug substance. The expiration of such core patents would typically be around 20 years from the filing date, subject to extensions.
Method of Use Patents: Patents also cover specific medical uses of vamorolone, such as its application in treating Duchenne muscular dystrophy. These patents protect the therapeutic indications.
- Patents related to the treatment of DMD often claim methods of administering vamorolone to patients with this condition. The specific claims and their expiration dates are critical for defining the period of market exclusivity for the therapeutic indication.
Manufacturing Process Patents: While less publicly detailed, patents or trade secrets may protect specific manufacturing processes for vamorolone, particularly novel synthesis routes or purification methods that offer advantages in yield, purity, or cost-effectiveness. These can provide an additional layer of protection against generic competition.
Formulation Patents: Patents may also cover specific formulations of vamorolone, such as the oral suspension, which could enhance stability, palatability, or bioavailability.
- For example, patents describing specific excipients or manufacturing methods for the oral suspension can extend market protection.

The duration and scope of these patents directly influence the period of market exclusivity for vamorolone, impacting investment decisions and competitive strategies. Santhera actively manages its patent portfolio to maximize its intellectual property protection.

What is the Current Status of Vamorolone's Commercialization and Supply Chain Readiness?

Santhera Pharmaceuticals is actively pursuing the commercialization of vamorolone, with significant progress in clinical development and regulatory submissions. This commercial push directly impacts supply chain readiness.

Regulatory Submissions and Approvals:
- Vamorolone has received Orphan Drug Designation in the U.S. and Europe for DMD.
- Santhera has submitted marketing authorization applications (MAAs) to the EMA and a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA). The review processes for these applications are ongoing or have recently concluded.
- As of late 2023 and early 2024, regulatory decisions from these agencies are anticipated or have been issued, directly influencing commercial launch timelines and supply chain activation.
Commercial Launch Preparations:
- Santhera has been actively preparing for the commercial launch of vamorolone in key markets. This includes building out its commercial infrastructure, engaging with healthcare providers, and ensuring sufficient inventory is available.
- The company has indicated that it has secured manufacturing capacity through its partners, including Catalent, to meet projected market demand upon approval.
Supply Chain Scale-Up:
- Upon regulatory approval, the supply chain will transition from clinical trial supply to commercial scale manufacturing. This requires a seamless handover from development and small-scale production to large-scale GMP manufacturing.
- Santhera and its manufacturing partners, Catalent and API suppliers, must ensure that processes are validated for commercial volumes and that quality control systems are robust enough to support continuous production.
Market Access and Distribution:
- Post-approval, Santhera will establish distribution channels to make vamorolone available to patients. This involves working with wholesale distributors, pharmacies, and healthcare systems.
- Ensuring a reliable and efficient distribution network is crucial for timely patient access.

The successful commercialization of vamorolone hinges on the seamless integration of regulatory approvals with a fully functional and scaled commercial supply chain.

What are the Challenges and Risks Associated with Vamorolone's Supply Chain?

The supply chain for vamorolone, like any novel pharmaceutical product, faces several potential challenges and risks that could impact its availability and cost.

Manufacturing Complexity: The synthesis of vamorolone API and its formulation into a stable oral suspension may involve complex chemical processes and specialized equipment. Any deviation or difficulty in scaling these processes can lead to production delays or increased costs.
Reliance on Specific Suppliers: Vamorolone's supply chain relies on a limited number of specialized partners, particularly for API manufacturing and finished drug product formulation. Any disruption at these key suppliers, due to capacity issues, quality problems, or financial instability, could severely impact product availability.
- For instance, a major issue at Catalent or a critical API CMO could halt production.
Regulatory Hurdles: Delays in regulatory approvals or unexpected requirements from health authorities can impact commercial launch timelines and the activation of the full commercial supply chain. Post-approval regulatory changes or inspections can also pose risks.
Quality Control and Assurance: Maintaining consistent product quality across different manufacturing batches and suppliers is critical. Any lapse in quality control could lead to product recalls, regulatory action, and significant damage to brand reputation.
Geopolitical and Economic Factors: Global supply chains are susceptible to disruptions from geopolitical events, trade disputes, natural disasters, and economic fluctuations that can affect the availability and cost of raw materials or increase transportation expenses.
Intellectual Property Challenges: The potential for patent challenges from generic manufacturers post-exclusivity or litigation over patent infringement could impact market exclusivity and the financial viability of the supply chain investments.
Cost Management: The specialized nature of vamorolone manufacturing can lead to high production costs. Effectively managing these costs while ensuring product quality and regulatory compliance is an ongoing challenge.

Proactive risk management strategies, including supplier diversification where feasible, robust quality agreements, contingency planning, and continuous monitoring of the supply chain, are essential for mitigating these risks.

Who are the Key Stakeholders in Vamorolone's Supply Chain?

The vamorolone supply chain involves a network of interconnected entities, each playing a critical role in bringing the drug from development to patients.

Santhera Pharmaceuticals: The primary stakeholder and innovator responsible for the development, regulatory approval, commercialization, and overall management of the vamorolone supply chain.
Catalent Pharma Solutions: The contract development and manufacturing organization (CDMO) responsible for the manufacturing of the finished drug product.
API Contract Manufacturing Organizations (CMOs): Third-party manufacturers responsible for synthesizing the active pharmaceutical ingredient (API) of vamorolone. Specific names are typically proprietary but operate under contract with Santhera.
Regulatory Agencies: Bodies such as the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) that oversee the quality, safety, and efficacy of vamorolone through their approval and inspection processes.
Raw Material Suppliers: Companies that provide the necessary chemical precursors, solvents, and excipients for API synthesis and drug product formulation.
Logistics and Distribution Partners: Companies responsible for the transportation, warehousing, and distribution of vamorolone from manufacturing sites to wholesalers, pharmacies, and ultimately, patients.
Patients and Patient Advocacy Groups: The ultimate beneficiaries of the supply chain. Patient advocacy groups often play a role in raising awareness and advocating for access to treatments like vamorolone.
Healthcare Providers: Physicians, pharmacists, and hospitals who prescribe and administer vamorolone to patients.

Effective collaboration and communication among these stakeholders are essential for ensuring a seamless and reliable supply of vamorolone.

Key Takeaways

Vamorolone's API manufacturing is managed by Santhera Pharmaceuticals, likely through qualified third-party CMOs specializing in complex organic synthesis.
Catalent Pharma Solutions is the primary CDMO responsible for the finished drug product manufacturing of vamorolone.
The supply chain is governed by stringent GMP regulations from agencies like the FDA and EMA, necessitating robust quality control and regulatory compliance at all stages.
Intellectual property protection for vamorolone includes composition of matter, method of use, and potentially manufacturing process and formulation patents, with core patents providing market exclusivity.
Santhera is actively pursuing commercialization, with supply chain readiness contingent on regulatory approvals and scaled manufacturing capacity.
Key challenges include manufacturing complexity, reliance on specialized suppliers, regulatory hurdles, and quality control.
Stakeholders encompass Santhera, CDMOs, regulatory bodies, logistics partners, healthcare providers, and patients.

Frequently Asked Questions

What is the primary therapeutic indication for which vamorolone is being developed? Vamorolone is being developed for the treatment of Duchenne muscular dystrophy (DMD), a rare genetic disorder characterized by progressive muscle degeneration.
How does vamorolone differ from existing DMD treatments like corticosteroids? Vamorolone is designed as a dissociative anti-inflammatory steroid, meaning it aims to retain the anti-inflammatory benefits of corticosteroids while potentially reducing side effects associated with traditional steroids, such as effects on growth, bone metabolism, and the hypothalamic-pituitary-adrenal (HPA) axis.
What is the current regulatory status of vamorolone in the United States and Europe? Santhera Pharmaceuticals has submitted marketing authorization applications (MAAs) to the European Medicines Agency (EMA) and a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for vamorolone for the treatment of DMD. Regulatory decisions from these agencies were anticipated in late 2023 and early 2024.
Are there any other drugs in development or on the market that use a similar supply chain model or are manufactured by the same key suppliers? Catalent Pharma Solutions, as a major CDMO, manufactures a wide range of pharmaceutical products for various companies. Santhera Pharmaceuticals itself may utilize similar supply chain management strategies for other investigational drugs in its pipeline. Specific overlaps in API manufacturing would depend on the proprietary nature of those contracts.
What is the expected timeframe for vamorolone to become commercially available if approved? Following regulatory approval, Santhera has indicated that it is prepared for a commercial launch. The exact timeline would depend on the timing of the regulatory decisions and the subsequent readiness of the distribution network, but typically a launch can occur within several months of approval.

Citations

[1] U.S. Food and Drug Administration. (n.d.). Current Good Manufacturing Practice (CGMP) Regulations. Retrieved from https://www.fda.gov/drugs/pharmaceutical-quality-and-compliance/current-good-manufacturing-practice-cgmp-regulations

[2] European Commission. (n.d.). EudraLex Volume 4 – Good Manufacturing Practice. Retrieved from https://ec.europa.eu/health/human-use/eudralex/volume-4

Suppliers and packagers for generic pharmaceutical drug: vamorolone

vamorolone

Vamorolone Drug Supply Chain Analysis